🔗 Visit the ClinicalTrials.gov page for NCT01652976
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Trial watch: Chemotherapy with immunogenic cell death inducers. | Oncoimmunology | 2013 | 1.31 |
| 2 | Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. | J Hematol Oncol | 2015 | 0.91 |
| 3 | Src inhibition is still a relevant target in pancreatic cancer. | Oncologist | 2014 | 0.81 |
| 4 | Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. | World J Gastroenterol | 2016 | 0.77 |
| 5 | Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells. | Br J Pharmacol | 2015 | 0.76 |
| 6 | Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology. | Therap Adv Gastroenterol | 2016 | 0.75 |